Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

During the development of indazolylpyrimidines as novel and potent inhibitors of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR2) tyrosine kinase, we observed that some human tumour xenografts are more sensitive to VEGFR2 kinase inhibitors than others. A better understanding of the basi...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Dev, I K, Dornsife, R E, Hopper, T M, Onori, J A, Miller, C G, Harrington, L E, Dold, K M, Mullin, R J, Johnson, J H, Crosby, R M, Truesdale, A T, Epperly, A H, Hinkle, K W, Cheung, M, Stafford, J A, Luttrell, D K, Kumar, R
Format: Artigo
Język:Inglês
Wydane: Nature Publishing Group 2004
Hasła przedmiotowe:
Experimental Therapeutics
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409895/
https://ncbi.nlm.nih.gov/pubmed/15328520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602109
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy